Loss of DAB2IP Contributes to Cell Proliferation and Cisplatin Resistance in Gastric Cancer

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Sagaert X, Topal B, et al. Gastric cancer. Lancet. 2016;388:2654–2664. doi:10.1016/S0140-6736(16)30354-3
   PubMed Web of Science ®Google Scholar
• Ajani JA, Lee J, Sano T, et al. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017;3:17036. doi:10.1038/nrdp.2017.36
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Kamiyama K, Sawada S, Fukuda T, et al. A case of long-term survival following two-stage surgery for perforated advanced gastric cancer caused by chemotherapy. Gan to Kagaku Ryoho. 2019;46:701–704.
   PubMedGoogle Scholar
• Ghosn M, Tabchi S, Kourie HR, et al. Metastatic gastric cancer treatment: second line and beyond. World J Gastroenterol. 2016;22(11):3069–3077. doi:10.3748/wjg.v22.i11.3069
   PubMed Web of Science ®Google Scholar
• Bellazzo A, Di Minin G, Collavin L, et al. Block one, unleash a hundred. Mechanisms of DAB2IP inactivation in cancer. Cell Death Differ. 2017;24:15–25. doi:10.1038/cdd.2016.134
   PubMed Web of Science ®Google Scholar
• Liu L, Xu C, Hsieh J-T, et al. DAB2IP in cancer. Oncotarget. 2016;7:3766–3776. doi:10.18632/oncotarget.6501
   PubMedGoogle Scholar
• Duan Y, Yin X, Lai X, et al. Upregulation of DAB2IP inhibits Ras activity and tumorigenesis in human pancreatic cancer cells. Technol Cancer Res Treat. 2020;19:1–11. doi:10.1177/1533033819895494
   Web of Science ®Google Scholar
• Yun EJ, Lin CJ, Dang A, et al. Downregulation of human DAB2IP gene expression in renal cell carcinoma results in resistance to ionizing radiation. Clin Cancer Res. 2019;25(14):4542–4551. doi:10.1158/1078-0432.CCR-18-3004
   PubMed Web of Science ®Google Scholar
• Fan X, Wang Y, Fan J, et al. Deletion of SMURF 1 represses ovarian cancer invasion and EMT by modulating the DAB2IP/AKT/Skp2 feedback loop. J Cell Biochem. 2019;120(6):10643–10651. doi:10.1002/jcb.28354
   PubMed Web of Science ®Google Scholar
• Wang B, Gu Q, Li J. DOC-2/DAB2 interactive protein regulates proliferation and mobility of nasopharyngeal carcinoma cells by targeting PI3K/Akt pathway. Oncol Rep. 2017;38(1):317–324. doi:10.3892/or.2017.5704
   PubMed Web of Science ®Google Scholar
• Zhu XH, Wang JM, Yang SS, et al. Down-regulation of DAB2IP promotes colorectal cancer invasion and metastasis by translocating hnRNPK into nucleus to enhance the transcription of MMP2. Int J Cancer. 2017;141(1):172–183. doi:10.1002/ijc.30701
   PubMed Web of Science ®Google Scholar
• Wang B, Huang J, Zhou J, et al. DAB2IP regulates EMT and metastasis of prostate cancer through targeting PROX1 transcription and destabilizing HIF1α protein. Cell Signal. 2016;8(11):1623–1630. doi:10.1016/j.cellsig.2016.07.011
   Google Scholar
• Shen YJ, Kong ZL, Wan FN, et al. Downregulation of DAB2IP results in cell proliferation and invasion and contributes to unfavorable outcomes in bladder cancer. Cancer Sci. 2014;105(6):704–712. doi:10.1111/cas.12407
   PubMed Web of Science ®Google Scholar
• Xie D, Gore C, Zhou J, et al. DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc Natl Acad Sci U S A. 2009;106(47):19878–19883. doi:10.1073/pnas.0908458106
   PubMed Web of Science ®Google Scholar
• Wu K, Xie D, Zou Y, et al. The mechanism of DAB2IP in chemoresistance of prostate cancer cells. Clin Cancer Res. 2013;19(17):4740–4749. doi:10.1158/1078-0432.CCR-13-0954
   PubMed Web of Science ®Google Scholar
• Wu K, Wang B, Chen Y, et al. DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling. Cell Signal. 2015;27(12):2515–2523. doi:10.1016/j.cellsig.2015.09.014
   PubMed Web of Science ®Google Scholar
• Zhou J, Luo J, Wu K, et al. Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies. Oncogene. 2016;35(35):4663–4674. doi:10.1038/onc.2016.4
   PubMed Web of Science ®Google Scholar
• Tao Y, Sun C, Zhang T, et al. SMURF1 promotes the proliferation, migration and invasion of gastric cancer cells. Oncol Rep. 2017;38(3):1806–1814. doi:10.3892/or.2017.5825
   PubMed Web of Science ®Google Scholar
• Sun L, Yao Y, Lu T, et al. DAB2IP downregulation enhances the proliferation and metastasis of human gastric cancer cells by derepressing the ERK1/2 pathway. Gastroenterol Res Pract. 2018;2018:2968252. doi:10.1155/2018/2968252
   PubMed Web of Science ®Google Scholar
• Ni QF, Zhang Y, Yu JW, et al. miR-92b promotes gastric cancer growth by activating the DAB2IP-mediated PI3K/AKT signalling pathway. Cell Prolif. 2020;53(1):e12630. doi:10.1111/cpr.12630
   PubMed Web of Science ®Google Scholar
• Cheng Z, Shao X, Xu M, et al. Rab1A promotes proliferation and migration abilities via regulation of the HER2/AKT-independent mTOR/S6K1 pathway in colorectal cancer. Oncol Rep. 2019;41(5):2717–2728. doi:10.3892/or.2019.7071
   PubMed Web of Science ®Google Scholar
• Xu M, Shao X, Kuai X, et al. Expression analysis and implication of Rab1A in gastrointestinal relevant tumor. Sci Rep. 2019;9(1):13384. doi:10.1038/s41598-019-49786-7
   PubMedGoogle Scholar
• Li W, Wang L, Ji XB, et al. MiR-199a inhibits tumor growth and attenuates chemoresistance by targeting K-RAS via AKT and ERK signalings. Front Oncol. 2019;9:1071. doi:10.3389/fonc.2019.01071
   PubMed Web of Science ®Google Scholar
• Wang T, Chen G, Ma X, et al. MiR-30a regulates cancer cell response to chemotherapy through SNAI1/IRS1/AKT pathway. Cell Death Dis. 2019;10(3):153. doi:10.1038/s41419-019-1326-6
   PubMedGoogle Scholar
• Pan CW, Jin X, Zhao Y, et al. AKT-phosphorylated FOXO1 suppresses ERK activation and chemoresistance by disrupting IQGAP1-MAPK interaction. EMBO J. 2017;36(8):995–1010. doi:10.15252/embj.201695534
   PubMed Web of Science ®Google Scholar
• Xu Y, He J, Wang Y, et al. miR-889 promotes proliferation of esophageal squamous cell carcinomas through DAB2IP. FEBS Lett. 2015;589:1127–1135. doi:10.1016/j.febslet.2015.03.027
   PubMed Web of Science ®Google Scholar
• Liao H, Xiao Y, Hu Y, et al. MicroRNA-32 induces radioresistance by targeting DAB2IP and regulating autophagy in prostate cancer cells. Oncol Lett. 2015;10:2055–2062. doi:10.3892/ol.2015.3551
   PubMed Web of Science ®Google Scholar